The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...

Therini Bio anticipates using the proceeds to fund Phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as ...

LONDON (Reuters) -U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion ...